SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。SELECT是一项III期、双盲、安慰剂对照临床试验，旨在评估硒和维生素E（单独或联合）对前列腺癌发病率的影响，并通过常规临床管理来确定。累计目标是在全国范围内招募32400名55岁或以上的健康男性（非裔美国男性为50岁或以上）。研究期限为12年，统一应计期为5年。参与者将从随机分组开始接受研究补充，直到试验结束，根据参与者被随机分组的时间，在7到12年之间。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E (individually and in combination) on the incidence of prostate cancer as determined by routine clinical management. The accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men). Study duration will be twelve years with a five-year uniform accrual period. Participants will receive study supplements from the time of their randomization until the end of the trial period, between seven and twelve years depending upon when the participant was randomized.